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Abstract
OBJECTIVE: The aim of this study was to evaluate the
expression of topoisomerase IIa (TOP2A) in epithelial
and stromal cells of ovarian cancer.METHODS: TOP2A
expression was analyzed in normal ovarian tissue
and in laser-microdissected ovarian tumor epithelial
and adjacent stromal cells using quantitative real time
RT-PCR (n = 38), RNA in situ hybridization (n = 13), and
immunhistochemistry (n = 69). Results: TOP2A mRNA
was detected by RNA in situ hybridization in all ovarian
cancer samples, with stronger hybridization signals in
tumor epithelial cells compared to adjacent stromal
cells. The same expression pattern was found by im-
munohistochemistry (P = .0001). Very interestingly,
specific changes of TOP2A were found in recurrent
ovarian cancer after platinum-based chemotherapy:
TOP2A expression decreased in tumor epithelial cells
(P = .056) of recurrent ovarian cancer, whereas it in-
creased in tumor adjacent stromal cells (P = .023) com-
pared to primary ovarian cancer.CONCLUSION: TOP2A
mRNA and protein expressions in ovarian cancer ex-
hibit specific patterns in tumor epithelial and adjacent
stromal cells, which are differentially modulated after
platinum-based chemotherapy. These data support the
possible importance of the stromal compartment in
tumor progression and suggest that tumor stromal
cells might be relevant to the development of chemo-
therapy resistance in ovarian cancer.
Neoplasia (2006) 8, 38–45
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Introduction
Ovarian cancer is one of the most common malignancies
in women and is the leading cause of death from all malig-
nancies of the female genital tract in the western world [1].
The standard treatment is radical tumor-reductive surgery
followed by platinum-based combination chemotherapy
[2]. Although complete response is seen in 40% to 60% of
cases, the majority of patients relapse and develop chemo-
therapy resistance, limiting the success of treatment [2].
Various drugs have demonstratedmoderate efficacy under these
circumstances, with response rates ranging from 14% to 34%
[3]. However, remission observed with single-agent schedules
is usually partial and has short duration, and this is especially
true in cases of platinum-refractory tumors [3]. Better understand-
ing of the mechanisms of chemotherapy resistance could poten-
tially improve the management of recurrent ovarian cancer.
DNA topoisomerases are nuclear enzymes that are es-
sential for DNA replication, RNA transcription, chromosomal
condensation, and mitotic chromatid separation [4–7]. Type II
topoisomerases are cellular targets of clinically active anticancer
drugs, such as etoposide and doxorubicin, in the management
of recurrent ovarian cancer [8–10]. Topoisomerase-targeted
agents stabilize a transient covalent enzyme–DNA complex,
which produces DNA strand cleavage and apoptosis [11]. It is
known that alterations of topoisomerase enzymatic activity re-
sult in atypical multidrug resistance [12,13]. There are two dif-
ferent isoforms of topoisomerase II, namely topoisomerase IIa
(TOP2A) and topoisomerase IIb, which have distinct biochemi-
cal, pharmacological, and physiological properties [14].
To date, some studies have focused on TOP2A. Unlike
topoisomerases I and IIb, which are expressed constitutively
throughout the cell cycle, TOP2A expression occurs only in the
S andG2–Mphases [15]. The TOP2A gene encodingTOP2A is
located on chromosome 17q21–22, and it is often coamplified
in various tumor entities, including ovarian cancer, with the
HER2 oncogene, which is also located in 17q21.1 [16–22]. Fur-
thermore, experimental data suggest that the tumor-suppressor
gene p53, which is located on chromosome 17p13.1, regulates
the minimal promoter of TOP2A, making TOP2A one of the
downstream targets for p53-dependent regulation of cell cycle
progression in human cells [23]. TOP2A has been previously
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implicated in contributing to drug resistance in ovarian cancer
[21,22,24–27], but its expression does not seem to predict
drug resistance as strong as other factors do [28].
In the present study, TOP2A expression has been care-
fully analyzed in stromal and tumor epithelial cells of primary
and recurrent ovarian cancers—the latter after platinum-
based chemotherapy. To overcome the problem of histo-
logic heterogeneity of ovarian malignancies, due to variable
amounts of stromal cells, tumor epithelial cells, and large
areas of necrosis [29], we applied laser-supported micro-
dissection to obtain pure subpopulations of tumor epithelial
and stromal cells. Our data demonstrate a change in the
TOP2A expression of tumor epithelial and adjacent stromal
cells in recurrent ovarian cancer after platinum-based chemo-
therapy, which may be important for the development of
chemoresistance in ovarian cancer.
Materials and Methods
Tissue Specimens
Ovarian cancer samples were obtained from 62 patients
after surgical treatment at the Department of Gynecology of
the Charite´ University Hospital (Tumor Bank Ovarian Cancer,
Berlin,Germany). Thirty-four of 62 patients hadprimary tumors
and had never been treated with chemotherapy prior to sur-
gery, whereas the remaining 28 had recurrent disease and had
been previously treated with platinum-based chemotherapy
(platinum/paclitaxel,n=24;platinum/cyclophosphamide,n=4).
After excision, one part of the tissue sample was immediately
stored in liquid nitrogen, whereas a second part was trans-
ferred into 4% formalin and embedded in paraffin. All samples
were histologically examined on hematoxylin–eosin sections
by a pathologist. Patient details, including tumor histology,
grade and stage, ascites, and residual tumor, are summa-
rized in Table 1. The International Federation of Obstetrics
and Gynecology (FIGO) classification was used for clini-
cal staging, and Gynecologic Oncology Group criteria were
used for histologic grading [30]. The Ethics Committee of the
Charite´ University Hospital approved the study protocol. Pre-
operative consent was obtained from each patient using
written basic information. Borderline ovarian tumors were ex-
cluded from the study because they represent a distinct bio-
logic entity [31].
Laser Microdissection and RNA Extraction
To isolate pure cell subpopulations from tumor specimens,
laser-captured microdissection was used following standard
protocol [32,33] with some modifications. Serial 7-mm frozen
tissue sections were cut in a cryostat and mounted on a sterile
2.5-mmmembrane, fixed immediately in 70%ethanol, counter-
stainedwith hematoxylin–eosin, and air-dried. Themembrane
was turned upside-down and fixed with adhesive tape on a
second sterile slide. The first slide served as a template, on
which the areas of tumor were marked. Areas of interest were
selected under microscopy, aided by visual control software
[Molecular Machines and Industries (MMI), Glattbrugg, Swit-
zerland]. On consecutive sections, tumor epithelial cells and
adjacent stromal cells were microdissected using a UV laser
microdissection system (MMI) and capture transfer films (Arc-
turus GmbH, Moerfelden-Walldorf, Germany). Microdissected
groups of cells were pooled and collected in ice-cold tubes,
containing 50 ml of guanidine isothiocyanate buffer with 2%
b-mercaptoethanol. Special care was taken during all steps of
preparation to avoid contamination. Total RNA was extracted
from 30 mm2 of microdissected tissues for each sample using
the guanidine isothiocyanate/cesium chloride method [34].
PicoGreen (Molecular Probes, Eugene, OR) was used for
RNA quality control.
Quantitative Reverse Transcription–Polymerase
Chain Reaction (RT-PCR)
Single-stranded cDNA was synthesized with Omniscript
Reverse Transcriptase Kit (Qiagen, Hilden, Germany), ac-
cording to the protocol supplied by the manufacturer. Real-
time PCR was performed using Gen Amp 5700 sequence
detection system (PE Applied Biosystems, Weiterstadt, Ger-
many) using intron-spanning primers and Fam (5V end)–
labeled and Tamra (3V end)–labeled specific oligonucleotides.
The housekeeping gene GAPDH was used as reference.
Primers and theTaqManprobewere designedusing thePrimer
Express software (PEApplied Biosystems). The sequences for
the: 1) forward primer, 2) TaqMan probe, and 3) reverse primer
were as follows: for TOP2A: 1) 5V-AAG GAA CTA AAA GGG
ATC CAG CTT-3V, 2) Fam-5V-TGT CTC TCA AAA GCC TGA
TCC TGC CAA-3V-Tamra, and 3) 5V-TTT GCGGCG ATT CTT
GGT-3V; forGAPDH: 1) 5V-GAA GGT GAAGGT CGG AGT C-
3V, 2) Fam-5V-CAA GCT TCC CGT TCT CAG CC-3V-Tamra,
and 3) 5V-GAA GAT GGT GAT GGG ATT TC-3V.
Table 1. Patients’ Clinicopathological Characteristics.
Parameter Primary Cancer
(Untreated Patients)
Recurrent Cancer
(Platinum-Treated
Patients)
Ovarian cancer samples 34 (54.8%) 28 (45.2%)
Age at treatment
[median (range)] (years)
56 (30–86) 50.5 (26–68)
Histology
Serous–papillary 21 (61.8%) 25 (89.3%)
Endometrioid 8 (23.5%) 2 (7.1%)
Mucinous 2 (5.9%) 1 (3.6%)
Mixed/others 3 (8.8%) 0
FIGO stage
I 8 (23.5%) 2 (7.1%)
II 1 (2.9%) 0
III 13 (38.2%) 19 (67.9%)
IV 12 (35.3%) 7 (25%)
Histologic grade
I 5 (14.7%) 6 (21.4%)
II 10 (29.4%) 9 (32.1%)
III 19 (55.9%) 13 (46.4%)
Ascites
None 9 (26.5%) 18 (64.3%)
<500 ml 13 (38.2%) 5 (17.9%)
>500 ml 12 (35.3%) 5 (17.9%)
Postoperative residual
tumor mass
Macroscopically tumor-free 23 (67.6%) 11 (39.3%)
V2 cm 6 (17.7%) 12 (42.9%)
>2 cm 5 (14.7%) 5 (17.9%)
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The following PCR reaction mixture in a total volume of
25 ml was used: 1 ng of total RNA; 0.2 mM forward and reverse
primers; 0.2 mM TaqMan probe; 500 mM dATP, dCTP, dGTP,
and dUTP; 3.5 mM MgCl2; 1.25 U of AmpliTaq Gold; and
12.5 U of AmpErase UNG in 1 TaqMan buffer. Signals were
detected with a fluorescence-measuring instrument in real-
time (ABI Prism 7700 Sequence Detector; PE Applied Bio-
systems). Relative RNA quantification was performed with the
CT method, as described by the manufacturer, normalizing CT
values to the housekeeping geneGAPDH [35] and calculating
the relative expression values of tumor tissues with respect to
nonmalignant, noninflammatory ovarian tissue RNA (Clontech,
Heidelberg,Germany),whichwas used as normal. All real-time
RT-PCR experiments were performed in triplicate standard.
Only RNA samples from laser-microdissected tissues with
good overall RNA quality (CT < 31 for the housekeeping gene
GAPDH) were included in the final analysis.
Nonradioisotopic RNA In Situ Hybridization
TOP2A expression on the mRNA level was analyzed with
nonradioisotopic in situ hybridization in tissue sections from
13 ovarian tumors. An IMAGE cDNA clone for TOP2A (Gen-
Bank accession no. AA047124) was obtained from Incyte
Genomics (St. Louis, MO) and verified by sequencing. Label-
ing, quantification, hybridization, and detection for DIG mRNA
probes were performed according to supplier protocol (Roche
Diagnostics, Mannheim, Germany). TOP2A antisense probe
was labeled with DIG UTP by in vitro transcription, precipitated
with ethanol, and dissolved in DEPC–H2O. In a prehybridiza-
tion step, 5-mm paraffin-embedded ovarian cancer slides were
deparaffinized, alcohol-rehydrated, fixed in 4% PFA, and pre-
treated with Proteinase K. For hybridization, slides were incu-
bated with 2.5 ng/ml TOP2A RNA probe for 12 to 14 hours at
65jC. Stringent posthybridization washes were performed at
60jC using 20% (wt/vol) formamide and 0.5 SSC. Signal de-
tection was achieved by incubation with alkaline phosphatase–
labeled anti-DIG antibody, developed with BM purple substrate,
and counterstained with nuclear fast red. Hybridization with
TOP2AmRNA sense probe was performed in parallel for each
slide as negative control.
Immunohistochemistry
The avidin–biotin complex (ABC) method was used for the
staining of TOP2A in formalin-fixed, paraffin-embedded tis-
sues. Series from each tissue sample were cut into 4-mm sec-
tions. During deparaffinization, endogenous peroxidase
activity was quenched with a hydrogen peroxide solution. For
antigen retrieval, slides were incubated in citrate buffer (pH
6.0) and heated for 20 minutes in a pressure cooker. Non-
specific binding sites were blocked with CAS-blocking solution
(Dako, Hamburg, Germany). After cooling at room tempera-
ture, slides were incubated with TOP2A primary antibody (Ki-
S1 clone; Roche, Penzberg, Germany) for 1 hour. Detection
was accomplished by incubation of biotinylated secondary
antibody, followed by the tertiary ABC complex, which bound
to biotin on the secondary antibody. Slides were then devel-
opedwith anAECSubstrate Kit (Zymed Laboratories Inc., San
Francisco, CA). Sections were counterstained with hema-
toxylin. Negative controls were performed usingwater, instead
of antibodies. A total of 62 samples from ovarian tumors and
7 normal ovarian tissue samples used as controls were
analyzed immunohistochemically for TOP2A with Ki-S1 anti-
body. Hematoxylin–eosin staining was performed for basic
histology, and one slide was stained without primary antibody
for negative control.
Semiquantitative Scoring Interpretation
A semiquantitative scoring system was used for the eval-
uation of immunohistochemical and in situ hybridization data,
as described previously [36]. A minimum of 1000 cells (ap-
proximately 10 high-power fields) were counted to determine
the percentage of positive cells. Mean dye intensity was as-
sessed using the following scale: 0 = negative, 1 = low, 2 =
middle, and 3 = strong. The percentages of stained cells varied
as follows: 0, negative; 1, <10%; 2, 10% to 50%; 3, 51% to 80%;
4, >80% positive cells. According to the scores, tissues were
classified as having low (0–2 points), middle (3–6 points), or
strong (7–12 points) TOP2A expression.
Statistical Analysis
Statistical analysis was performed using SPSS statistical
software for Windows (SPSS, Inc., Chicago, IL). To compare
expression levels between different cell groups (tumor versus
stroma, and primary versus recurrent), the Mann-Whitney U
test was used. The correlation of TOP2A expression with
histopathological type, FIGO stage, histologic grade, resid-
ual tumor, ascites, age at diagnosis, and overall survival was
evaluated with univariate and multivariate analyses with
the Cox regression model. P < .05 was considered statisti-
cally significant.
Results
Quantitative RT-PCR of TOP2A mRNA in Ovarian Cancer
TOP2A expression in laser-microdissected tumor epithe-
lial and adjacent stromal cells from ovarian tumors was
analyzed by real-time RT-PCR. Only microdissected tissue
samples with optimal RNA quality (CT < 31 for the house-
keeping gene GAPDH; see Materials and Methods section)
were included in the final analysis. This criterion was fulfilled
by 38 RNA preparations, representing 16 RNA samples from
microdissected tumor stromal cells and 22 RNA samples
from microdissected ovarian tumor epithelial cells.
Figure 1A illustrates real-time RT-PCR data for TOP2A
mRNA expression in stromal cells of primary and recurrent
ovarian cancers. Compared to a control RNA from a normal
nonmicrodissected ovary mainly containing normal stromal
cells (Clontech; named ‘‘Ref’’ in Figure 1A), TOP2A mRNA
was upregulated in 13 of 16 (81%) preparations of tumor
stromal cells, indicating that TOP2A overexpression in tumor
stroma is a general feature of primary and recurrent ovarian
cancers. Comparing TOP2A mRNA expression between
stromal cells of primary and recurrent ovarian cancers, we
found a more abundant expression in stromal cells from
platinum-treated patients compared to nontreated patients
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(P = .017) (Figure 1B); however, the opposite was found
for TOP2A expression in tumor epithelial cells (i.e., more
abundant expression in primary ovarian cancer than in re-
current ovarian cancer, but this was not statistically signifi-
cant) (P = .97).
Cellular Localization of TOP2A mRNA and Protein
TOP2A mRNA expression was detected with nonradio-
isotopic in situ hybridization in tissue sections from ovarian
tumors (n = 13). Representative staining patterns of TOP2A
mRNA in primary and recurrent ovarian cancers are shown in
Figure 2. Abundant TOP2A mRNA expression was detect-
able in tumor cells from primary serous papillary tumors
(Figure 2A, arrows); weak TOP2A expression was also
detectable in adjacent stromal cells (Figure 2A, arrowheads).
In recurrent serous papillary ovarian cancer, TOP2A mRNA
expression was detectable in tumors (Figure 2D, arrows), but
it was less abundant than the expression found in primary
tumors (cf. Figure 2, A and D). However, TOP2A mRNA ex-
pression increased in stromal cells of recurrent ovarian cancer
(Figure 2D, arrowheads), both with respect to the number of
stained cells and staining intensity. Hybridization with the
TOP2A sense (control) probe did not lead to any nonspecific
signals in the control sections (Figure 2, B and E ).
Next, we analyzed TOP2A protein expression by immuno-
histochemistry using the well-characterized TOP2A-specific
antibody Ki-S1 (Figure 3). Immunohistochemical analysis
showed strong nuclear localization of the TOP2A protein,
consistently with previously reported findings for the Ki-S1
antibody [37]. We analyzed TOP2A protein expression in
the surface epithelium of normal ovary and inclusion cysts
(derivatives of normal surface epithelium) (n = 7), primary
Figure 1. (A) Real-time RT-PCR data showing the upregulation of TOP2A mRNA expression in tumor-adjacent stromal cells after platinum-based chemotherapy.
Relative TOP2Aexpression levels in tumor stromaof primary ovarian cancer (P) and recurrent ovarian cancer (R) are compared.Ref =Reference tissues (normal ovary).
(B) TOP2A expression in tumor-adjacent stromal cells of primary and recurrent ovarian cancers. Box plot presentation of real-time RT-PCR data. TOP2A mRNA
expression was more abundant in stromal cells from platinum-treated recurrent tumors compared to expression of primary ovarian cancer in stromal cells (P = .017).
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ovarian cancer (n = 34), and recurrent ovarian cancer after
platinum-based chemotherapy (n = 28). In ovarian inclusion
cysts (Figure 3, A–C) and ovary surface epithelium (data not
shown), TOP2A protein was hardly detectable in epithelial
cells and surrounding stromal tissues (Figure 3A; Figure 3B,
scale up of stromal cell area). Very strong TOP2A protein
expression was detected in tumor cells of primary ovarian
cancer (Figure 3D, arrows). A smaller number of adjacent
Figure 2. TOP2A mRNA detection using nonradioactive mRNA in situ hybridization. (A–C) Primary ovarian cancer. (D–F) Recurrent ovarian cancer. (A + D)
Antisense probe. (B + E) Sense (control) probe. (C + F) Hematoxylin –eosin staining. TOP2A mRNA is detected in tumor cells (arrows) and tumor-adjacent stromal
cells (arrowheads). The sense probes in (B) + (E) do not show any signal. Scale bar = 50 m.
Figure 3. Immunohistochemical analysis of TOP2A protein expression in nonmalignant ovarian tissues (A–C), primary ovarian cancer (D–F), and recurrent tumor
(G– I). (B), (E), and (H) are scale up of the boxed regions shown in (A), (D), and (G), respectively. (C), (F), and (I) are hematoxylin –eosin stainings of consecutive
sections. (A) TOP2A protein expression in the epithelium of inclusion cysts and in surrounding stromal cells is hardly detectable. (D) Primary ovarian cancer is
characterized by very abundant TOP2A expression in tumor epithelial cells (arrows) and a clearly detectable TOP2A expression in tumor-adjacent stromal cells
(arrowheads). (G) TOP2A protein expression in recurrent ovarian cancer after platinum-based chemotherapy. Expression in tumor cells decreased (asterisk)
compared to that in primary cancer, whereas TOP2A expression in tumor-adjacent stromal cells (arrowheads) increased. Scale bar = 50 m.
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stromal cells clearly demonstrated TOP2A protein expression
in the nucleus as well (Figure 3D, arrowhead; Figure 3E, scale
up of boxed stromal cell region). In recurrent tumors after
platinum-based chemotherapy, TOP2A protein expression was
still highly abundant in a proportion of tumor cells (Figure 3G,
arrow), whereas other tumor cells expressed TOP2A protein
only moderately (asterisk), indicating a decrease in overall
TOP2A expression in these tumor cells. However, TOP2A
protein expression in the stromal compartment of recurrent
ovarian cancer increased (Figure 3G, arrowheads; Figure 3H,
scale up of boxed stromal cell area), both with respect to the
number of stained cells and staining intensity.
After counting 10 microscopic high-power fields, with
at least 1000 counted cells per specimen, immunoreactive
scores (seeMaterials andMethods section) were determined
and statistically analyzed. The results are shown as box plots
in Figure 4. TOP2A protein was overexpressed in both stro-
mal and tumor cells from tumor tissues (Figure 4, four boxes
on the left) compared to normal ovarian tissues (Figure 4, two
boxes on the right) (P = .0001). Consistent with RNA in situ
hybridization data, TOP2A protein expression in primary and
recurrent ovarian cancers was clearly more abundant in
tumor cells compared to adjacent stromal cells (P < .01). Con-
sistent with our quantitative RT-PCR data, TOP2A protein ex-
pression increased in stromal cells from platinum-treated
tumors compared to stromal cells of primary tumors (P =
.056). An inverse correlation was found for tumor cells (i.e.,
decreased expression in tumor cells from platinum-treated
patients compared to nontreated patients) (P = .023). No
significant correlation was found between TOP2A expres-
sion in tumor and stromal cells on the mRNA and protein
levels and in clinicopathological data (histopathological type,
FIGO stage, histologic grade, residual tumor, ascites, age
at diagnosis.
Discussion
Systematic gene expression analysis presented in this
study shows, for the first time, distinctTOP2A expression pat-
terns in tumor and adjacent stromal cells in ovarian cancer.
TOP2A expression was much more abundant in tumor cells
compared to adjacent stromal cells on both the protein and
mRNA levels. Moreover, a specific pattern of TOP2A expres-
sion was found on the mRNA and protein levels with respect
to platinum-based chemotherapy: TOP2A expression was
clearlymore abundant in tumor cells from nontreated patients
compared to platinum-treated patients, whereas the inverse
pattern was found in stromal cells (i.e., more abundant
TOP2A expression in stromal cells from tumor relapses after
platinum chemotherapy compared to stromal cells in tumors
of nontreated patients).
These differences in TOP2A expression in tumor epithe-
lium and adjacent stroma cells may reflect different effects of
platinum chemotherapy on the two cell subpopulations and
underscore a possible role of stromal cells in ovarian tumor
progression and failure of chemotherapy. To date, various
studies have focused on the mechanisms governing the
development of chemotherapy resistance in different tumor
entities, implicating a role for TOP2A [6,21,22,24–27,38,39]
and suggesting that TOP2A expression in tumor cells could
be used to predict responses to chemotherapy [18,19,
21–24]. Our results suggest, for the first time, a possible role
for tumor stroma in the development of drug resistance, and
this possibility should be evaluated in future studies. Fur-
thermore, analysis of TOP2A expression in subpopulations
of tumor and adjacent stromal cells could lead to the devel-
opment of methods that allow a more accurate prediction
of response to therapy.
The significantly higher expression of TOP2A in tumor
stroma after platinum-based chemotherapy is an important
Figure 4. Box plot presentation of immunohistochemical TOP2A expression data. TOP2A protein expression in primary (nontreated) and recurrent (platinum-
treated) ovarian tumors, as well as in normal ovarian tissues, is shown. TOP2A protein expression is reduced in tumor epithelial cells from platinum-treated patients
(P = .023), compared to its expression in epithelial tumor cells of untreated patients. In the tumor stroma, the opposite was found: TOP2A protein was more
abundantly expressed in the stromal cells of recurrent ovarian cancer after platinum-based chemotherapy compared to stromal cells of primary tumors (P = .056).
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finding fromabiologic prospective. Stromal changes, together
with DNA mutations and tissue disorders, are considered to
be important factors contributing to the initiation and progres-
sion of epithelial cancers [40]. It has been previously shown
that stromal fibroblasts play an important role in tumorige-
nesis, by taking part in tissue repair and remodeling through
the activation and production of epithelial growth factors and
degrading enzymes [41–43]. Furthermore, there exists evi-
dence suggesting that epithelial tumors can activate adjacent
stromal fibroblasts, which in turn can promote the growth and
invasion of tumor cells [44]. Moreover, stromal cells can be
activated by different factors, such as stromelysin-1, platelet-
derived growth factor, or irradiation, and then promote malig-
nant progression of epithelial cells [45–47]. Particularly in
ovarian cancer, stromal activity has been previously impli-
cated in a hypothesis supporting an ovarian cancer-prone
preneoplastic phenotype [48]. This theory is based on find-
ings on ovaries from women with an inherited risk for ovarian
cancer, which contained two ormore of the followinghistologic
characteristics: surface epithelial pseudostratification, surface
epithelial papillomatosis, deep cortical invaginations with epi-
thelial inclusion cysts, and increased stromal activity [48].
In conclusion, systematic gene expression analysis, with
three independent methods, showed distinct TOP2A expres-
sion patterns: a chemotherapy-independent higherTOP2Aex-
pression in primary tumor compared to adjacent stromal cells,
aplatinum-chemotherapy–associatedpatternofTOP2Adown-
regulation in tumor cells, and upregulation in adjacent stromal
cells. These distinct expression patterns support the role of
tumor stroma interface in tumor progression and suggest that
it might play a role in mechanisms leading to drug resistance
and failure of response to chemotherapy.
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